カテゴリ： GlobalData, 企業調査, 日本

Shionogi & Co Ltd (4507)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Shionogi & Co Ltd (4507) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C5148
◆発行会社（調査会社）：GlobalData
◆発行日：2018年9月
◆ページ数：98
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing and marketing of pharmaceutical products, diagnostic reagents and medical devices. The company’s core pharmaceuticals product business offers drugs for the treatment of disorders in the areas of metabolism, infection, immunity and cancer pain. Shionogi also sells, distributes and provides information about diagnostic products in the fields of infectious diseases, cardiovascular diseases and allergies. The company operates a network of subsidiaries, branches, sales offices manufacturing plants and research laboratories across Japan, China, Taiwan, North America and Europe. Shionogi is headquartered in Osaka, Japan.

Shionogi & Co Ltd (4507) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shionogi & Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Venture Financing 17
Nemesis Bioscience Raises USD1.8 Million in Seed Funding 17
Partnerships 18
Sage Therapeutics and Shionogi Enter into Co-Development Agreement 18
Kyoto University and Shionogi Enter into Research Agreement 19
DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 20
PharmaIN Enters into Agreement with Shionogi 21
Shionogi and UMN Pharma Enter into Agreement 22
Clinigen Enters into Agreement with Shionogi 23
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 24
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 25
FunPep Enters into Research Agreement with Shionogi 27
Shionogi Enters into Research Agreement with NB Health Labs 28
Shionogi Enters into Research Agreement with Nissan Chemical Industries 29
Mundipharma Enters into Distribution Agreement with Shionogi 30
Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 31
ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 32
Shionogi to Enter into Agreement with TB Alliance 33
Kyoto University and Shionogi Enter into R&D Agreement 34
Licensing Agreements 35
Shionogi Enters into Licensing Agreement with Hsiri Therapeutics 35
Pharmbio Korea Enters into Licensing Agreement with Shionogi 36
Duchesnay Receives Rights for Osphena from Shionogi 37
Shionogi Enters into Licensing Agreement with University of Tokushima 38
F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 39
Shionogi Enters into Licensing Agreement with PeptiDream 40
Shionogi Enters into Licensing Agreement with FunPep 41
Shionogi Enters into Licensing Agreement with MedImmune 42
Shionogi Enters Into Licensing Agreement With Janssen Pharma 43
Shionogi Enters Into Licensing Agreement With OncoTherapy Science For Cancer Peptide Vaccines 44
Mundipharma Enters Into Licensing Agreement With Shionogi 45
Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 46
Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 47
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 48
Equity Offering 49
PharmaIN to Raise USD17 Million in Private Placement of Shares 49
Egalet Completes Private Placement Of Shares For US$15 Million 50
Debt Offering 51
Shionogi Announces Public offering of Convertible Bonds Due 2019 for USD168.5 Million 51
Asset Transactions 52
Kyowa Pharma to Acquire 21 Products from Shionogi 52
Pragma Pharma Acquires Keflex from Shionogi 53
Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 54
Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 55
ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 56
Merz Pharma Acquires Cuvposa from Shionogi 57
Shionogi & Co Ltd – Key Competitors 58
Shionogi & Co Ltd – Key Employees 59
Shionogi & Co Ltd – Locations And Subsidiaries 62
Head Office 62
Other Locations & Subsidiaries 62
Joint Venture 64
Recent Developments 65
Strategy And Business Planning 65
Apr 23, 2018: Shionogi Announces Establishment Of New Manufacturing Subsidiary In Japan 65
Feb 07, 2017: Shionogi to Announce Corporate Reorganization and Personnel Reassignment 66
Financial Announcements 70
Jul 30, 2018: Shionogi: Financial Results for the First Quarter of Fiscal Year 2018(Consolidated) 70
May 09, 2018: Shionogi : Financial Results for Fiscal Year 2017 71
Feb 05, 2018: Shionogi: Financial Results for the Third Quarter of Fiscal Year 2017(Consolidated) 73
Jul 31, 2017: Shionogi Reports Revenue Of JPY75 Billion In Q1 Fiscal 2018 74
May 10, 2017: Shionogi Reports Revenue Of JPY338.9 Billion In Fiscal 2016 75
Feb 02, 2017: Shionogi Reports Revenue Of JPY256.5 Billion In Third Quarter Ended December 31, 2016 76
Corporate Communications 77
Mar 19, 2018: Shionogi to Announce Executive Appointments 77
Mar 21, 2017: Shionogi to Announce Executive Appointments 78
Product News 79
10/04/2017: Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017 79
06/01/2017: Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented at the American Society for Microbiology Microbe Meeting 81
04/22/2017: Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin 83
04/18/2018: Shionogi to Present New Data on COT-143 at 2018 European Congress of Clinical Microbiology and Infectious Diseases 85
03/23/2017: FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain 86
01/12/2017: Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial 87
Product Approvals 88
Mar 30, 2017: Symproic (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan 88
Clinical Trials 89
May 30, 2018: Kissei Announces Negative Topline Results from the additional phase III Clinical Trial evaluating KPS-0373 (Development Code) for the Treatment of Spinocerebellar Ataxia 89
Mar 05, 2018: OncoTherapy Science: Announcement of the progress of Phase III clinical study of the cancer-specific peptide vaccine S-588410 90
Sep 28, 2017: Shionogi to Highlight Research on Cefiderocol (S-649266), A Siderophore Cephalosporin at IDWeek 2017 91
Jun 30, 2017: Announcement of milestone payment for the progress of Phase III clinical trial of the cancer-specific peptide vaccine S-588410 93
Apr 17, 2017: Shionogi to Present New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin at the 27th European Congress of Clinical Microbiology and Infectious Diseases 94
Other Significant Developments 96
Feb 28, 2018: Shionogi to Announce Corporate Reorganizations 96
Mar 22, 2017: PeptiDream Announces 1st Milestone from Macrocyclic Peptide Drug Discovery Alliance with Shionogi 97
Appendix 98
Methodology 98
About GlobalData 98
Contact Us 98
Disclaimer 98

List of Tables
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shionogi & Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shionogi & Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Nemesis Bioscience Raises USD1.8 Million in Seed Funding 17
Sage Therapeutics and Shionogi Enter into Co-Development Agreement 18
Kyoto University and Shionogi Enter into Research Agreement 19
DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 20
PharmaIN Enters into Agreement with Shionogi 21
Shionogi and UMN Pharma Enter into Agreement 22
Clinigen Enters into Agreement with Shionogi 23
Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 24
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 25
FunPep Enters into Research Agreement with Shionogi 27
Shionogi Enters into Research Agreement with NB Health Labs 28
Shionogi Enters into Research Agreement with Nissan Chemical Industries 29
Mundipharma Enters into Distribution Agreement with Shionogi 30
Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 31
ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 32
Shionogi to Enter into Agreement with TB Alliance 33
Kyoto University and Shionogi Enter into R&D Agreement 34
Shionogi Enters into Licensing Agreement with Hsiri Therapeutics 35
Pharmbio Korea Enters into Licensing Agreement with Shionogi 36
Duchesnay Receives Rights for Osphena from Shionogi 37
Shionogi Enters into Licensing Agreement with University of Tokushima 38
F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 39
Shionogi Enters into Licensing Agreement with PeptiDream 40
Shionogi Enters into Licensing Agreement with FunPep 41
Shionogi Enters into Licensing Agreement with MedImmune 42
Shionogi Enters Into Licensing Agreement With Janssen Pharma 43
Shionogi Enters Into Licensing Agreement With OncoTherapy Science For Cancer Peptide Vaccines 44
Mundipharma Enters Into Licensing Agreement With Shionogi 45
Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 46
Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 47
Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 48
PharmaIN to Raise USD17 Million in Private Placement of Shares 49
Egalet Completes Private Placement Of Shares For US$15 Million 50
Shionogi Announces Public offering of Convertible Bonds Due 2019 for USD168.5 Million 51
Kyowa Pharma to Acquire 21 Products from Shionogi 52
Pragma Pharma Acquires Keflex from Shionogi 53
Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 54
Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 55
ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 56
Merz Pharma Acquires Cuvposa from Shionogi 57
Shionogi & Co Ltd, Key Competitors 58
Shionogi & Co Ltd, Key Employees 59
Shionogi & Co Ltd, Other Locations 62
Shionogi & Co Ltd, Subsidiaries 63
Shionogi & Co Ltd, Joint Venture 64

List of Figures
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Shionogi & Co Ltd (4507)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • BOC Aviation Limited (2588)：企業の財務・戦略的SWOT分析
    BOC Aviation Limited (2588) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Old Dominion Electric Cooperative：企業の戦略的SWOT分析
    Old Dominion Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • T-System Inc-医療機器分野：企業M&A・提携分析
    Summary T-System Inc (T-System) is a healthcare service provider that offers clinical, financial, operational, and regulatory solutions. The company offers documentation solutions, which include EV, an emergency department information system; EV for physicians, a solution with ER-specific clinical c …
  • Ansaldo STS SpA：企業の戦略・SWOT・財務情報
    Ansaldo STS SpA - Strategy, SWOT and Corporate Finance Report Summary Ansaldo STS SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • University of Gothenburg：製薬・医療：M&Aディール及び事業提携情報
    Summary University of Gothenburg is an educational institute that offers medical education and research services. The institute provides undergraduate, postgraduate, degree programs, and distance education programs. It offers courses in the fields of natural sciences, education teaching and learning …
  • Yonsei University：製薬・医療：M&Aディール及び事業提携情報
    Summary Yonsei University (Yonsei) is an educational service provider that offers training and research services. The university offers graduation programs in various areas such as applied statistics, architectural engineering, Asian studies, astronomy, atmospheric sciences, biochemistry, bio conver …
  • CMP Pharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary CMP Pharma Inc (CMP Pharma), formerly Carolina Medical Products Company Inc is a specialty pharmaceutical company that develops and manufactures generic prescription, non-prescription and skin care products. The company’s prescription products include SPS suspension, isoniazid oral solution …
  • Peace River Electric Cooperative, Inc.：発電所・企業SWOT分析
    Peace River Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informati …
  • Ariba Inc：企業の戦略的SWOT分析
    Ariba Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Sampo plc：企業のM&A・事業提携・投資動向
    Sampo plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sampo plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Rollprint Packaging Products Inc.：企業の戦略・SWOT・財務情報
    Rollprint Packaging Products Inc. - Strategy, SWOT and Corporate Finance Report Summary Rollprint Packaging Products Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Hague and London Oil PLC：石油・ガス：M&Aディール及び事業提携情報
    Summary Hague and London Oil PLC (HALO), formerly Wessex Exploration plc, is an oil and gas exploration company that develops resource properties. The company acquires, explores, produces, and develops oil and gas resource properties across the UK. Its projects comprise assets in the Philippines, Gu …
  • Ascopiave SpA (ASC)：企業の財務・戦略的SWOT分析
    Ascopiave SpA (ASC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Mondi Plc (MNDI)：企業の戦略的SWOT分析
    Mondi Plc (MNDI) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Bonavista Energy Corp (BNP)：石油・ガス：M&Aディール及び事業提携情報
    Summary Bonavista Energy Corp (Bonavista) is an intermediate energy company, which acquires, explores for, develops and produces oil and natural gas from its assets in the provinces of Alberta, British Columbia and Saskatchewan. Its core operations are concentrated in the Glauconite and Falher plays …
  • Arla Foods Ingredients Group P/S：戦略・SWOT・企業財務分析
    Arla Foods Ingredients Group P/S - Strategy, SWOT and Corporate Finance Report Summary Arla Foods Ingredients Group P/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Baltimore Gas and Electric Co：企業の戦略的SWOT分析
    Baltimore Gas and Electric Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Genzyme Corp：医療機器：M&Aディール及び事業提携情報
    Summary Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty care treatments targeting rare diseases, oncology, immunology and multiple sclerosis. It offers products for the treatment of indications including various forms of cancer, mucopolysaccharidosi …
  • LG International Corp (001120)：企業の財務・戦略的SWOT分析
    LG International Corp (001120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Air Products and Chemicals Inc (APD)：企業の財務・戦略的SWOT分析
    Air Products and Chemicals Inc (APD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆